Abstract: This present disclosure relates to the use of syncytiotrophoblast-derived microvesicles for diagnosing and/or monitoring a subject with preeclampsia. Accordingly, this disclosure provides for methods for isolating, purifying, and/or detecting syncytiotrophoblast-derived microvesicles from a biological fluid of a pregnant subject. The present disclosure also provides kits for diagnosing a subject with preeclampsia, where the kit contains reagents useful for isolating, purifying, and/or identifying the syncytiotrophoblast-derived microvesicles in a biological sample and for detecting one or more biomarkers present on the surface of or within the syncytiotrophoblast-derived microvesicles.

Abstract: This present disclosure relates to the use of one or more biomarkers for diagnosis, screening, or monitoring aortic aneurysm disease (e.g., ascending aortic aneurysm, descending thoracic aortic aneurysm, abdominal aortic aneurysm and Marfan syndrome) in a biological sample (e.g., a blood sample) of a subject. Accordingly, this disclosure provides methods and kits for determining the presence of one or more biomarkers for aortic aneurysm disease in a biological sample of a subject; methods for using the presence of such biomarkers to predict or diagnose aortic aneurysm disease in a subject; and methods to select or modify a therapeutic regimen (e.g., a beta-blocker treatment) for a subject based on the use of such biomarkers.

Abstract: This present disclosure relates to the use of one or more biomarkers to monitor the conditional state of an organ or tissue, including transplanted tissue, or disease state, including diabetes, in a biological sample of a subject. Accordingly, this disclosure provides for: methods and kits for determining the presence of one or more biomarkers for organ or tissue rejection/injury or diabetes in a biological sample of a subject; methods for using the presence of such biomarkers to predict or diagnose organ or tissue rejection/injury or diabetes in a subject; and methods to select or modify a therapeutic regimen for a subject based on the use of such biomarkers.